Ignyta 10-K 14 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	RXDX
Entity Registrant Name	IGNYTA, INC.
Entity Central Index Key	1,557,421
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		41,700,063
Entity Public Float			$ 114.1

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 24,340	$ 46,383
Short-term investment securities	83,637	85,420
Other current assets	3,873	4,191
Total current assets	111,850	135,994
Long-term investment securities	24,983	40,346
Property and equipment, net	6,270	18,764
Other long-term assets	1,811	410
Total assets	144,914	195,514
Current liabilities:
Accounts payable and accrued liabilities	13,510	14,025
Accrued compensation and benefits	4,007	3,844
Current portion of term debt		6,675
Total current liabilities	17,517	24,544
Term debt, net of current portion and discount	29,517	22,821
Other long-term liabilities	3,110	12,164
Total liabilities	50,144	59,529
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value; 150,000,000 shares authorized; 41,665,779 and 32,339,081 shares issued and outstanding at December 31, 2016 and 2015, respectively	4	3
Additional paid-in capital	346,549	284,252
Accumulated other comprehensive loss	(123)	(249)
Accumulated deficit	(251,660)	(148,021)
Total stockholders' equity	94,770	135,985
Total liabilities and stockholders' equity	$ 144,914	$ 195,514

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	41,665,779	32,339,081
Common stock, shares outstanding	41,665,779	32,339,081

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue			$ 150
Operating expenses:
Research and development	$ 76,926	$ 73,511	30,505
General and administrative	23,758	17,069	9,506
Total operating expenses	100,684	90,580	40,011
Loss from operations	(100,684)	(90,580)	(39,861)
Other income (expense):
Interest expense	(3,214)	(2,593)	(1,362)
Interest income and other income/ (expense), net	955	715	1,233
Loss on debt extinguishment	(696)
Total other income (expense)	(2,955)	(1,878)	(129)
Net loss	(103,639)	(92,458)	(39,990)
Comprehensive loss:
Net loss	(103,639)	(92,458)	(39,990)
Net unrealized gain (loss) on investment securities	126	(196)	(53)
Comprehensive loss	$ (103,513)	$ (92,654)	$ (40,043)
Net loss per share:
Net loss per share - basic and diluted	$ (2.69)	$ (3.44)	$ (2.18)
Weighted average shares - basic and diluted	38,480	26,854	18,328

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Comprehensive Income/(Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2013	$ 41,788	$ 1	$ 57,360		$ (15,573)
Beginning balance, shares at Dec. 31, 2013		13,934,876
Common stock offering, net	51,582	$ 1	51,581
Common stock offering, net shares		6,031,750
Exercise of stock options	7		7
Exercise of stock options, shares		18,143
Repurchase of unvested restricted stock	(1)		(1)
Repurchase of unvested restricted stock, shares		(400,000)
Reclassification of warrant from liability	125		125
Issuance of warrants to lender	208		208
Stock-based compensation	2,283		2,283
Unrealized gain (loss) on investments	(53)			$ (53)
Net loss	(39,990)				(39,990)
Ending balance at Dec. 31, 2014	55,949	$ 2	111,563	(53)	(55,563)
Ending balance, shares at Dec. 31, 2014		19,584,769
Common stock offering, net	141,589	$ 1	141,588
Common stock offering, net shares		9,944,464
Other issuances of common stock	25,296		25,296
Other issuances of common stock, shares		2,713,000
Exercise of stock options	391		391
Exercise of stock options, shares		74,529
Net exercise of warrants	0	$ 0	0	0	0
Net exercise of warrants, shares		22,319
Issuance of warrants to lender	69		69
Stock-based compensation	5,345		5,345
Unrealized gain (loss) on investments	(196)			(196)
Net loss	(92,458)				(92,458)
Ending balance at Dec. 31, 2015	135,985	$ 3	284,252	(249)	(148,021)
Ending balance, shares at Dec. 31, 2015		32,339,081
Common stock offering, net	53,892	$ 1	53,891
Common stock offering, net shares		9,200,000
Exercise of stock options	$ 410		410
Exercise of stock options, shares	126,698	126,698
Issuance of warrants to lender	$ 275		275
Stock-based compensation	7,721		7,721
Unrealized gain (loss) on investments	126			126
Net loss	(103,639)				(103,639)
Ending balance at Dec. 31, 2016	$ 94,770	$ 4	$ 346,549	$ (123)	$ (251,660)
Ending balance, shares at Dec. 31, 2016		41,665,779

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities:
Net loss	$ (103,639)	$ (92,458)	$ (39,990)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on debt extinguishment	696
In-process research and development charge associated with asset acquisition		11,880
Issuance of common stock for technology		13,416
Stock-based compensation	7,721	5,345	2,283
Depreciation and amortization of property and equipment	3,478	2,037	528
Amortization of premium on investment securities, net of accretion of discounts	688	1,358	887
Amortization of non-cash financing costs	593	538	368
Other	(358)	2
Change in operating assets and liabilities:
Prepaid expenses and other assets	(509)	(2,700)	(801)
Accounts payable	95	2,856	164
Accrued expenses and other liabilities	1,125	6,926	4,073
Net cash used in operating activities	(90,110)	(50,800)	(32,488)
Investing activities:
Purchases of investment securities	(123,857)	(148,111)	(89,286)
Maturities of investment securities	84,755	90,662	18,058
Sales of investment securities	55,746
Purchases of property and equipment	(2,451)	(3,522)	(3,117)
Proceeds from sale of equipment	75		16
Net cash provided by / (used in) investing activities	14,268	(60,971)	(74,329)
Financing activities:
Proceeds from issuance of common stock, net of issuance costs	53,892	141,589	51,582
Proceeds from borrowings under term loan facility	17,116	10,000	21,000
Repayments of borrowings under term loan facility	(17,438)		(11,050)
Proceeds from exercise of stock options	410	391	7
Other	(181)	(172)	(180)
Net cash provided by financing activities	53,799	151,808	61,359
Net increase/ (decrease) in cash and cash equivalents	(22,043)	40,037	(45,458)
Cash and cash equivalents at beginning of period	46,383	6,346	51,804
Cash and cash equivalents at end of period	24,340	46,383	6,346
Supplemental disclosure of cash flow information:
Cash paid for interest	2,611	2,528	1,884
Amounts accrued for purchases of property and equipment	357
Non-cash financing activity:
Net change in capitalized costs associated with leased building (Note 5)	(11,000)	11,000
Final loan fee and warrant issuance recorded as debt discount	1,600	369	838
Unrealized gain (loss) on available-for-sale investment securities	$ 126	$ (196)	(53)
Leasehold improvements paid by lessor			2,342
Assets acquired under capital leases			538
Warrant reclassified to equity due to removal of anti-dilution provision			$ 125

Organization

Organization	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. ORGANIZATION Organization and Nature of Operations Ignyta, Inc. (“Ignyta” or the “Company”) is incorporated in the state of Delaware and was founded in 2011 (with the name “NexDx, Inc.”). The Company changed its name to “Ignyta, Inc.” on October 8, 2012. Ignyta is a biotechnology company focused on precision medicine in oncology. Its goal is not just to shrink tumors, but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations. The Company is pursuing an integrated therapeutic (“Rx”) and companion diagnostic (“Dx”) strategy for treating patients with cancer. Its Rx efforts are focused on in-licensing On October 31, 2013, the Company merged with and into IGAS Acquisition Corp., a wholly owned subsidiary of Ignyta, Inc., a Nevada corporation previously named “Infinity Oil & Gas Company” (“Parent”), formerly a “shell company” under applicable rules of the Securities and Exchange Commission (the “SEC”). The Company changed its name to Ignyta Operating, Inc. in connection with this merger, and it survived the merger as a wholly owned subsidiary of Parent. In the merger, Parent acquired the business of the Company and continued the business operations of the Company. The merger was accounted for as a reverse merger and recapitalization, with the Company as the acquirer and Parent as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the merger are those of the Company and are recorded at the historical cost basis of the Company, and the financial statements after completion of the merger will include the assets and liabilities of Parent and the Company, the historical operations of the Company and the operations of the combined enterprise of Parent and the Company from and after the closing date of the merger. On June 12, 2014, Parent merged with and into the Company, with the Company surviving the merger and changing its name to “Ignyta, Inc.” (the “Reincorporation Merger”). This Reincorporation Merger had no material impact on the accounting of the Company. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment. Liquidity The Company had negative cash flow from operations of approximately $90.1 million during 2016 and, as of December 31, 2016, had an accumulated deficit of approximately $251.7 million. The Company is focused primarily on its development programs, and management believes such activities will result in the continued incurrence of significant research and development and other expenses related to those programs. The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. If the clinical trials for any of the Company’s products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of its product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. The Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders. As of December 31, 2016, the Company had cash, cash equivalents and investment securities totaling $133.0 million. While the Company expects that its existing cash, cash equivalents and investment securities will enable it to fund its operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market on its own. Failure to obtain adequate financing could eventually adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with United States generally accepted accounting principles (“GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures. Significant estimates used in preparing the financial statements include those assumed in estimating expenses for the Company’s pre-clinical Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. These changes had no impact on the Company’s total assets or reported net loss. Cash, Cash Equivalents and Investment Securities The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents represent bank demand deposits and amounts invested in money market funds. Investment securities are considered to be available-for-sale Fair Value of Financial Instruments Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The valuation of assets and liabilities is subject to fair value measurements using a three tiered approach, and fair value measurement is classified and disclosed in one of the following categories: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Cash, cash equivalents, investment securities are carried at fair value (see Note 3). Other current assets, accounts payable and accrued expenses, and other liabilities are carried at costs which represents a reasonable estimate of fair value due to the short-term nature of these items. The carrying value of the term debt approximates its fair value as the interest rate and other terms are that which is currently available to the Company. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates can be subjective, involve uncertainties and matters of judgment, and therefore cannot be determined with precision. Credit Risk Financial instruments that may subject the Company to credit risk consist of cash, cash equivalents, investment securities and term loan obligations. The Company maintains demand deposits with financial institutions in amounts that typically exceed the amount of federal insurance provided on such deposits. Investment securities are invested in accordance with the Company’s investment policy which specifies the categories, allocations, and ratings of securities that may be considered for investment. Management does not believe that the Company’s cash equivalents and investment securities have a significant risk of default or illiquidity. The primary exposure to market risk with respect to investment securities and the Company’s term loans is the risk that prevailing interest rates change causing the value of the investment securities and the value of the obligation owed under term loans to fluctuate. Sources of supply The Company relies on third-party manufacturers and single source third-party suppliers to manufacture its preclinical and clinical drug supplies for use in the conduct of preclinical studies and clinical trials. If the Company’s third-party manufacturers are unable to continue manufacturing our preclinical and clinical drug supplies, or if it lost the single source suppliers used in the manufacturing process, it may not be able to meet the demand to support ongoing clinical trials. The Company also does not currently have arrangements in place for the commercial supply of bulk drug substance or drug products. It may not be able to establish these or any other supply relationship when needed, on reasonable terms, or at all. Any failure to secure sufficient supply of its product candidates for preclinical or clinical testing or, in the future, for commercial purposes, would materially harm the Company’s operations and financial results. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Asset lives range from three to seven years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term. Maintenance and repairs are expensed as incurred. The Company establishes assets and corresponding financing liabilities for the construction costs incurred under build-to-suit The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. To date, the Company has not experienced any significant impairment losses on its property and equipment. Research and Development Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of (i) external research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational sites and consultants; (ii) employee-related expenses, including salaries, benefits, travel and stock compensation expense; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies, and (v) license fees and other expenses relating to the acquisition of rights to development programs. The Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors and other information. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses. Clinical Trial and Pre-Clinical The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known to it at that time. Accrued expenses for pre-clinical Income Taxes Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities. The Company follows the accounting guidance on accounting for uncertainty in income taxes. The guidance prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. Stock-Based Compensation Stock-based compensation cost for equity awards to employees and directors is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option-pricing model. The value of the award that is ultimately expected to vest is recognized as an expense under the straight-line method over the requisite service period (generally the vesting period of the equity grant). Any changes to the estimated forfeiture rates are accounted for prospectively. Stock options issued to non-employees non-employees re-measured Comprehensive Income (Loss) Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner available-for-sale Net Loss per Share Basic and diluted net loss per share has been computed by dividing net loss by the weighted average number of common shares outstanding. The calculations of net loss per share exclude potentially dilutive securities (consisting of outstanding options, warrants and restricted stock units) of approximately 5.5 million and 5.4 million shares as of December 31, 2016 and 2015, respectively, as inclusion of these securities would be anti-dilutive for each of the years shown in the financial statements given the net loss position of the Company. Recently Adopted Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU’) 2015-03 In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740) – Balance Sheet Classification of Deferred Taxes Recent Accounting Pronouncements On August 26, 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In March 2016, the FASB issued ASU 2016-09, Compensation–Stock Compensation: Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities

Investment Securities

Investment Securities	12 Months Ended
	Dec. 31, 2016
Investments Schedule [Abstract]
Investment Securities	3. INVESTMENT SECURITIES The Company reports its available-for-sale available-for-sale in thousands As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Available-for-sale Commercial paper $ 8,996 $ — $ — $ 8,996 Corporate debt securities 49,179 1 (55 ) 49,125 U.S. government and agency obligations 50,568 1 (70 ) 50,499 Total $ 108,743 $ 2 $ (125 ) $ 108,620 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Available-for-sale Commercial paper $ 7,992 $ — $ — $ 7,992 Corporate debt securities 94,959 3 (180 ) 94,782 U.S. government and agency obligations 23,064 — (72 ) 22,992 Total $ 126,015 $ 3 $ (252 ) $ 125,766 All of the Company’s available-for-sale available-for-sale None of the Company’s available-for-sale available-for-sale

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. FAIR VALUE MEASUREMENTS Available-for-sale The fair value of cash, cash equivalents and available-for-sale in thousands As of December 31, 2016 As of December 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 24,340 $ — $ — $ 24,340 $ 46,383 $ — $ — $ 46,383 Investment securities: Commercial paper — 8,996 — 8,996 — 7,992 — 7,992 Corporate debt securities — 49,125 — 49,125 — 94,782 — 94,782 U.S. government and government agency obligations 50,499 — — 50,499 22,992 — — 22,992 Total investment securities 50,499 58,121 — 108,620 22,992 102,774 — 125,766 Total assets measured at fair value $ 74,839 $ 58,121 $ — $ 132,960 $ 69,375 $ 102,774 $ — $ 172,149 The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 for the years ended December 31, 2016 and 2015. Instruments Not Recorded at Fair Value on a Recurring Basis The estimated fair value of the term loan is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar issues. The recorded value of the Company’s term loan approximates the current fair value due to the proximity to when the term loan was negotiated.

Balance Sheet Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	5. BALANCE SHEET DETAILS Property and Equipment Property and equipment consisted of the following ( in thousands December 31, 2016 December 31, 2015 Lab and manufacturing equipment $ 7,656 $ 6,941 Computer and office equipment 1,762 1,145 Leasehold improvements 374 2,349 Property and equipment at cost 9,792 10,435 Less accumulated depreciation and amortization (3,522 ) (2,671 ) Subtotal 6,270 7,764 Construction in process (see below) — 11,000 Property and equipment, net $ 6,270 $ 18,764 Lab and manufacturing equipment includes assets acquired in 2014 under leases accounted for as capital leases. These assets had an original acquisition value of $0.6 million, and a net book value of $0.4 million and $0.5 million as of December 31, 2016 and 2015, respectively. Depreciation related to these assets totaled $0.1 million in both fiscal 2016 and 2015, and $17,000 in fiscal 2014. Other Long-Term Liabilities Other long-term liabilities consisted of the following ( in thousands December 31, 2016 December 31, 2015 Leased facility financing obligation (see below) $ — $ 11,000 Final loan fee obligation to lender (see note 6) 1,600 930 Other long-term liabilities 1,510 234 Total $ 3,110 $ 12,164 Construction in Process and Leased Facility Financing Obligation In October 2015, the Company entered into an agreement for the lease of laboratory and office space on a build-to-suit build-out

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Note Payable	6. NOTE PAYABLE In June 2016, the Company entered into a term loan facility with Silicon Valley Bank, as collateral agent (“SVB”), and Oxford Finance LLC (“Oxford” and collectively with SVB, the “Lenders”). Under the loan facility, the Company received initial funding of $32.0 million, substantially all of which was used to repay the Company’s prior loan with SVB. The Company considered authoritative literature which states that modifications or exchanges are considered extinguishments with gains or losses recognized in current earnings if the terms of the new debt and original instrument are substantially different. The Company determined that for SVB’s portion of the new facility, the terms are not substantially different from the prior loan and should be accounted for as a debt modification with previously deferred financing costs amortized as an adjustment of interest expense over the remaining term of the modified debt using the interest method. The Company determined that the portion of the old facility with SVB that was not assumed by SVB under the new facility should be accounted for as a debt extinguishment with fees paid to the lender and previously deferred financing costs included in the calculation of loss on debt extinguishment. The Company recorded a loss on debt extinguishment of $0.7 million during the second quarter of fiscal 2016. Borrowings under the new facility will bear interest at a rate equal to the Prime Rate plus 4.35% (8.10% at December 31, 2016) and have interest only payments for twenty-four months, followed by a principal amortization period of thirty-six Upon the maturity date, the Company must make a final lump-sum In connection with this facility, the Company issued warrants to the Lenders to purchase an aggregate of approximately 94,116 shares of its common stock. The warrants are exercisable immediately, have a per-share exercisable immediately and have a term of seven years. Those warrants will be exercisable for an aggregate number of shares equal to $150,000 (which is 1.5% of the principal amount of the Second Tranche) divided by the lower of (a) the trailing 10-day Future minimum principal payments under the Company’s note payable are as follows ( in thousands Year ending December 31, Minimum Payments 2017 $ — 2018 5,333 2019 10,667 2020 10,667 2021 5,333 Total $ 32,000 The Company is bound by certain affirmative and negative covenants setting forth actions that it must and must not take during the term of the loan agreement, including a prohibition on the payment of dividends. Under the loan agreement, the Company must also maintain the majority of its cash in accounts at SVB. Upon the occurrence of an event of default, subject to cure periods for certain events of default, all amounts owed by the Company thereunder shall begin to bear interest at a rate that is 3% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lenders. The Company has granted SVB, as collateral agent for the ratable benefit of the Lenders, a security interest in substantially all of its personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed under this agreement. The Company has also agreed not to encumber any of its intellectual property without the required lenders’ prior written consent. The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations of the Company under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in the Company’s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, or a material impairment in the perfection or priority of lender’s lien in the collateral or in the value of such collateral. In the event of default by the Company under the Loan Agreement, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Loan Agreement, which could harm the Company’s financial condition. As of December 31, 2016, the Company was in compliance with all covenants under the Loan Agreement and there had been no material adverse change.

Asset Acquisition

Asset Acquisition	12 Months Ended
	Dec. 31, 2016
Text Block [Abstract]
Asset Acquisition	7. ASSET ACQUISITION In March 2015, under the terms of an asset purchase agreement with Cephalon, Inc. (“Cephalon”), an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva”), the Company acquired certain assets relating to certain oncology development programs, including Cephalon’s right, title and interest in and to certain intellectual property, compounds, products, contracts, records, data and development supplies related to the Company’s RXDX-105 RXDX-106 in-process

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	8. LICENSE AGREEMENTS Entrectinib The Company entered into a license agreement with Nerviano Medical Sciences S.r.l. (“NMS”) on October 10, 2013, which was amended on October 25, 2013, became effective on November 6, 2013, and was later amended on December 12, 2014. The license grants the Company exclusive global rights to develop and commercialize entrectinib. The Company’s development rights under the license are exclusive for the term of the agreement with respect to entrectinib and also, as to NMS, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of entrectinib, and include the right to grant sublicenses. The Company is obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on entrectinib at its expense. When and if commercial sales of a product begin, the Company will be obligated to pay NMS tiered royalties ranging from a mid-single Life-to-date up-front Taladegib On November 6, 2015, the Company entered into a license, development and commercialization agreement with Eli Lilly and Company (“Lilly”) under which the Company received exclusive, global rights to develop and commercialize pharmaceutical products under the licensed technology (“Licensed Products”), including Lilly’s product candidate taladegib. Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist that has achieved clinical proof-of-concept The terms of the license agreement provided for an up-front up-front mid-single mid-single RXDX-105 RXDX-106 In connection with the March 2015 asset acquisition from Cephalon, the Company assumed all rights and obligations under the collaboration agreement dated November 3, 2006, as amended April 17, 2009, between Cephalon, Inc. and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), as successor-in-interest product-by-product, country-by-country The Company is solely responsible for worldwide clinical development and commercialization of collaboration compounds, subject to the option of Daiichi Sankyo, exercisable during certain periods following completion of the first proof-of-concept co-develop co-promote RXDX-105. RXDX-105 The agreement requires the Company to make development, regulatory and sales milestone payments to Daiichi Sankyo of up to $44.5 million in the aggregate for RXDX-105, RXDX-106. RXDX-105 RXDX-106 mid-single RXDX-105 RXDX-106. product-by-product, country-by-country

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES Leases In October 2015, the Company entered into a non-cancellable build-to-suit The Company’s obligation to pay rent commenced in October 2016. The lease includes a free rent period and escalating rent payments and has a ten-year one-time nd The Company also leases other office space under operating leases that expire through 2018. These facility leases contain periodic rent increases that result in the Company recording deferred rent over the term of these leases. Rental expense under operating leases was $1.5 million, $0.6 million and $0.5 million for 2016, 2015 and 2014, respectively. Included in 2016 operating results is ground rental expense of $0.5 million recorded during the construction period of the Company’s new headquarters location. The Company’s non-cancellable (in thousands): Minimum 2017 $ 2,552 2018 4,572 2019 4,593 2020 4,731 2021 4,873 Thereafter 4,162 Total minimum lease payments $ 25,483 The Company has also entered into capital lease arrangements for the purchase of certain lab equipment. Future minimum lease payments under the Company’s capital lease obligations totaled $0.2 million as of December 31, 2016. Clinical Trial Study Agreement Commitments The Company has entered into agreements with several contract research organizations for clinical studies to be conducted both within and outside the U.S. for its product candidates. As of December 31, 2016, the total contracted cost under these arrangements was approximately $79.0 million, of which the Company had either paid or accrued total costs of approximately $30.6 million. These agreements run through various dates, with the longest term expected to run through 2020. These contracts can be terminated at any time with no more than 60 days’ notice, at which point the Company would be obligated to pay for costs incurred though the termination date. Other matters Although the Company is currently not a party to any material legal proceedings, in the normal course of business, the Company has been, and will likely continue to be, subject to claims, administrative proceedings or litigation incidental to its business that are either judged to be not material or that arise in the ordinary course of business from time to time, such as claims related to customer disputes, employment practices, wage and hour disputes, professional liability, licensure restrictions or denials, and patent infringement. Responding to such matters, regardless of whether they have merit, can be expensive and disruptive to normal business operations. Due to the uncertainties inherent in legal proceedings and litigation, the Company is not able to predict the timing or outcome of these matters. The Company could in the future incur judgments or enter into settlements of claims that could have an adverse effect on its results of operations in any particular period.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	10. STOCKHOLDERS’ EQUITY Authorized Shares The Company is authorized to issue 150,000,000 shares of common stock and 10,000,000 shares of preferred stock, with the preferred stock having the rights, preferences and privileges that the Company’s board of directors may determine from time to time. Each share of the Company’s common stock is entitled to one vote, and all shares rank equally as to voting and other matters. Stock Offerings In May 2016, the Company completed a public offering of an aggregate of 9,200,000 shares of its common stock for net proceeds of approximately $53.9 million (net of transaction costs of approximately $3.6 million). In November 2015, concurrent with its license agreement with Lilly (see Note 8), the Company issued and sold 1,500,000 shares of its common stock to Lilly for net proceeds of approximately $30.0 million (the transaction costs were negligible). The Company also entered into a registration rights agreement with Lilly pursuant to which the Company agreed to register the resale of the shares of the Company’s common stock held by Lilly. The Company may be liable for liquidated damages if it fails to timely file, obtain effectiveness or maintain the effectiveness of the registration statement. In June 2015, the Company completed a public stock offering providing for the issuance and sale to investors of an aggregate of 4,285,714 shares of its common stock for net proceeds of approximately $70.1 million (net of transaction costs of $4.9 million). In March 2015, concurrent with its asset purchase agreement with Cephalon (see Note 7), the Company issued and sold 4,158,750 shares of common stock to Cephalon and several additional investors in a registered direct offering. The net proceeds from this offering totaled approximately $41.4 million (net of transaction costs of $149,000). In March 2014, the Company completed a public stock offering providing for the issuance and sale to investors of an aggregate of 6,031,750 shares of its common stock for net proceeds of approximately $51.6 million (net of transaction costs of $3.6 million). At-The-Market In December 2015, the Company entered into an “at-the-market” Form S-3. Common Stock Warrants Warrants to purchase an aggregate of 153,472 shares of the Company’s common stock were outstanding at December 31, 2016. These warrants have a weighted average exercise price of $5.75 per share and expire at various dates through June 2023.

Equity Awards

Equity Awards	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Awards	11. EQUITY AWARDS Equity Incentive Plans The Company may issue equity awards to either employees or non-employees A summary of stock option activity during the year ended December 31, 2016, and other related information, is as follows: Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Term Aggregate Intrinsic Value Balance at December 31, 2015 5,250,941 $ 9.16 Granted 1,276,641 $ 8.17 Exercised (126,698 ) $ 3.24 Forfeited (1,291,599 ) $ 9.92 Balance at December 31, 2016 5,109,285 $ 8.86 7.85 $ 834,601 Exercisable at December 31, 2016 2,284,866 $ 8.00 6.91 $ 760,794 As of December 31, 2016, an aggregate of 3,525,680 shares remain available for grant under the Company’s equity incentive plan. Fair Value of Equity Awards The estimated weighted-average fair value of stock options granted during fiscal 2016, 2015 and 2014 was $5.25, $7.25 and $4.72 per share, respectively. The Company utilizes the Black-Scholes option pricing model to estimate the value of equity awards under its plans. The key valuation assumptions used in formulating these estimates include: • Volatility – • Expected Life of the Option Term – non-employee • Risk-Free Interest Rate – • Dividend Yield – The weighted-average assumptions used to estimate the fair value of stock option grants were as follows: Year ended December 31, 2016 2015 2014 Volatility 77 % 69 % 65 % Expected life of option 6.4 years 6.2 years 6.0 years Risk free interest rate 1.5 % 1.7 % 1.8 % Dividend yield — % — % — % Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. Restricted Stock Units (RSUs) During fiscal 2016 and 2015, the Company issued 206,880 and 90,000 RSUs, respectively, to members of its management team. As of December 31, 2016, a total of 238,480 of these RSUs were outstanding and subject to future vesting through January 2021. Stock-Based Compensation The following table summarizes stock-based compensation expense for all equity awards, including RSUs, issued to employees and non-employees in thousands Year ended December 31, 2016 2015 2014 Included in research and development $ 3,464 $ 2,576 $ 896 Included in general and administrative 4,257 2,769 1,387 Total $ 7,721 $ 5,345 $ 2,283 Unrecognized stock-based compensation expense related to unvested awards granted under the Company’s equity incentive plans totaled $15.5 million as of December 31, 2016, and is expected to be recognized over a weighted-average period of 2.6 years.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	12. INCOME TAXES The Company is subject to income taxes in the United States as well as certain state tax jurisdictions. The Company provides for income taxes under the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities, and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Due to its operating losses, the Company has not recorded a current or deferred income tax expense or benefit since its inception. A reconciliation of the statutory federal income tax provision to the actual income tax provision is as follows ( in thousands Year ended December 31, 2016 2015 2014 Expected income tax benefit at federal statutory rate $ (35,237 ) $ (31,436 ) $ (13,597 ) State income tax benefit, net of federal benefit (2,837 ) (5,438 ) (2,245 ) Research credits (3,480 ) (1,854 ) (1,118 ) Intangible related to asset acquisition — (1,247 ) — Uncertain tax positions 3,476 1,386 — Other 812 13 162 Change in valuation allowance 37,266 38,576 16,798 Income tax expense (benefit) $ — $ — $ — Included in the balance of unrecognized tax benefits at December 31, 2016 is $4.8 million that, if recognized, would not impact our income tax benefit or effective tax rate as long as our deferred tax asset remains subject to a full valuation allowance. We do not expect any significant increases or decreases to our unrecognized tax benefits within the next 12 months. The following table summarizes the changes in the amount of the Company’s unrecognized tax benefits ( in thousands Year ended December 31, 2016 2015 2014 Beginning balance $ 2,100 $ — $ — Increase (decrease) for prior year tax positions 5,267 2,100 — Increase (decrease) for current year tax positions — — — Income tax expense (benefit) $ 7,367 $ 2,100 $ — Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company’s net deferred tax asset has been fully offset by a valuation allowance. The significant components of the Company’s deferred tax assets are comprised of the following ( in thousands December 31, 2016 2015 Net operating loss carryforwards $ 68,427 $ 35,131 Tax credit carryforwards 6,571 3,224 Stock-based compensation 5,104 2,848 Accrued compensation 1,295 1,485 Intangible assets recognized for tax purposes 11,856 13,143 In process research and development charge 5,376 5,865 Other, net 680 846 Total deferred tax assets 99,309 62,542 Deferred tax liabilities (depreciation) (610 ) (1,060 ) Valuation allowance (98,699 ) (61,482 ) Net deferred tax assets $ — $ — At December 31, 2016, the Company had unused federal and state net operating loss (“NOL”) carryforwards of $192.3 million and $138.8 million, respectively, which will begin to expire in 2031. Approximately $1.0 million of these carryforwards relate to excess tax deductions for stock compensation, the benefit of which will be recorded as additional paid-in The utilization of NOL and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code (“IRC”), a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change The Company conducts intensive research and experimentation activities, generating research tax credits for Federal and state purposes under IRC section 41. The Company has not performed a formal study validating these credits claimed in the tax returns. Once a study is prepared, the amount of R&D tax credits available could vary from what was originally claimed on the tax returns. While the Company is not currently under any tax related examination, the tax years from 2012 through 2016 remain subject to examination by the taxing jurisdictions to which the Company is subject. The Company may be assessed interest and penalties related to the settlement of tax positions, and such amounts would be recognized within income tax expense when assessed.

Quarterly Data (unaudited)

Quarterly Data (unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (unaudited)	13. QUARTERLY DATA ( unaudited ) The following quarterly financial data, in the opinion of management, reflects all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of results for the periods presented (in thousands, except per share amounts): Year Ended December 31, 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Research and development expenses $ 19,781 $ 20,019 $ 16,626 $ 20,500 Total operating expenses $ 25,008 $ 25,518 $ 22,771 $ 27,387 Net loss $ (25,492 ) $ (26,651 ) $ (23,289 ) $ (28,208 ) Net loss per share – basic and diluted $ (0.79 ) $ (0.70 ) $ (0.56 ) $ (0.68 ) Year Ended December 31, 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Research and development expenses (1)(2) $ 20,215 $ 8,796 $ 10,432 $ 34,068 Total operating expenses $ 22,982 $ 12,651 $ 14,289 $ 40,658 Net loss $ (23,507 ) $ (13,120 ) $ (14,621 ) $ (41,210 ) Net loss per share – basic and diluted $ (1.15 ) $ (0.51 ) $ (0.49 ) $ (1.32 ) (1) First quarter 2015 results include an up-front non-cash (2) Fourth quarter 2015 results include an up-front non-cash

Organization (Policies)

Organization (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations Ignyta, Inc. (“Ignyta” or the “Company”) is incorporated in the state of Delaware and was founded in 2011 (with the name “NexDx, Inc.”). The Company changed its name to “Ignyta, Inc.” on October 8, 2012. Ignyta is a biotechnology company focused on precision medicine in oncology. Its goal is not just to shrink tumors, but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations. The Company is pursuing an integrated therapeutic (“Rx”) and companion diagnostic (“Dx”) strategy for treating patients with cancer. Its Rx efforts are focused on in-licensing On October 31, 2013, the Company merged with and into IGAS Acquisition Corp., a wholly owned subsidiary of Ignyta, Inc., a Nevada corporation previously named “Infinity Oil & Gas Company” (“Parent”), formerly a “shell company” under applicable rules of the Securities and Exchange Commission (the “SEC”). The Company changed its name to Ignyta Operating, Inc. in connection with this merger, and it survived the merger as a wholly owned subsidiary of Parent. In the merger, Parent acquired the business of the Company and continued the business operations of the Company. The merger was accounted for as a reverse merger and recapitalization, with the Company as the acquirer and Parent as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the merger are those of the Company and are recorded at the historical cost basis of the Company, and the financial statements after completion of the merger will include the assets and liabilities of Parent and the Company, the historical operations of the Company and the operations of the combined enterprise of Parent and the Company from and after the closing date of the merger. On June 12, 2014, Parent merged with and into the Company, with the Company surviving the merger and changing its name to “Ignyta, Inc.” (the “Reincorporation Merger”). This Reincorporation Merger had no material impact on the accounting of the Company. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Liquidity	Liquidity The Company had negative cash flow from operations of approximately $90.1 million during 2016 and, as of December 31, 2016, had an accumulated deficit of approximately $251.7 million. The Company is focused primarily on its development programs, and management believes such activities will result in the continued incurrence of significant research and development and other expenses related to those programs. The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. If the clinical trials for any of the Company’s products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of its product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. The Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders. As of December 31, 2016, the Company had cash, cash equivalents and investment securities totaling $133.0 million. While the Company expects that its existing cash, cash equivalents and investment securities will enable it to fund its operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market on its own. Failure to obtain adequate financing could eventually adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with United States generally accepted accounting principles (“GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures. Significant estimates used in preparing the financial statements include those assumed in estimating expenses for the Company’s pre-clinical
Reclassifications	Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. These changes had no impact on the Company’s total assets or reported net loss.
Cash, Cash Equivalents and Investment Securities	Cash, Cash Equivalents and Investment Securities The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents represent bank demand deposits and amounts invested in money market funds. Investment securities are considered to be available-for-sale
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The valuation of assets and liabilities is subject to fair value measurements using a three tiered approach, and fair value measurement is classified and disclosed in one of the following categories: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Cash, cash equivalents, investment securities are carried at fair value (see Note 3). Other current assets, accounts payable and accrued expenses, and other liabilities are carried at costs which represents a reasonable estimate of fair value due to the short-term nature of these items. The carrying value of the term debt approximates its fair value as the interest rate and other terms are that which is currently available to the Company. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates can be subjective, involve uncertainties and matters of judgment, and therefore cannot be determined with precision.
Credit Risk	Credit Risk Financial instruments that may subject the Company to credit risk consist of cash, cash equivalents, investment securities and term loan obligations. The Company maintains demand deposits with financial institutions in amounts that typically exceed the amount of federal insurance provided on such deposits. Investment securities are invested in accordance with the Company’s investment policy which specifies the categories, allocations, and ratings of securities that may be considered for investment. Management does not believe that the Company’s cash equivalents and investment securities have a significant risk of default or illiquidity. The primary exposure to market risk with respect to investment securities and the Company’s term loans is the risk that prevailing interest rates change causing the value of the investment securities and the value of the obligation owed under term loans to fluctuate.
Sources of supply	Sources of supply The Company relies on third-party manufacturers and single source third-party suppliers to manufacture its preclinical and clinical drug supplies for use in the conduct of preclinical studies and clinical trials. If the Company’s third-party manufacturers are unable to continue manufacturing our preclinical and clinical drug supplies, or if it lost the single source suppliers used in the manufacturing process, it may not be able to meet the demand to support ongoing clinical trials. The Company also does not currently have arrangements in place for the commercial supply of bulk drug substance or drug products. It may not be able to establish these or any other supply relationship when needed, on reasonable terms, or at all. Any failure to secure sufficient supply of its product candidates for preclinical or clinical testing or, in the future, for commercial purposes, would materially harm the Company’s operations and financial results.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Asset lives range from three to seven years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term. Maintenance and repairs are expensed as incurred. The Company establishes assets and corresponding financing liabilities for the construction costs incurred under build-to-suit The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. To date, the Company has not experienced any significant impairment losses on its property and equipment.
Research and Development	Research and Development Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of (i) external research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational sites and consultants; (ii) employee-related expenses, including salaries, benefits, travel and stock compensation expense; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies, and (v) license fees and other expenses relating to the acquisition of rights to development programs. The Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors and other information. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses.
Clinical Trial and Pre-Clinical Study Accruals	Clinical Trial and Pre-Clinical The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known to it at that time. Accrued expenses for pre-clinical
Income Taxes	Income Taxes Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities. The Company follows the accounting guidance on accounting for uncertainty in income taxes. The guidance prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost for equity awards to employees and directors is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option-pricing model. The value of the award that is ultimately expected to vest is recognized as an expense under the straight-line method over the requisite service period (generally the vesting period of the equity grant). Any changes to the estimated forfeiture rates are accounted for prospectively. Stock options issued to non-employees non-employees re-measured
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner available-for-sale
Net Loss per Share	Net Loss per Share Basic and diluted net loss per share has been computed by dividing net loss by the weighted average number of common shares outstanding. The calculations of net loss per share exclude potentially dilutive securities (consisting of outstanding options, warrants and restricted stock units) of approximately 5.5 million and 5.4 million shares as of December 31, 2016 and 2015, respectively, as inclusion of these securities would be anti-dilutive for each of the years shown in the financial statements given the net loss position of the Company.
Recently Adopted Accounting Standards / Recent Accounting Pronouncements	Recently Adopted Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU’) 2015-03 In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740) – Balance Sheet Classification of Deferred Taxes Recent Accounting Pronouncements On August 26, 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In March 2016, the FASB issued ASU 2016-09, Compensation–Stock Compensation: Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities
Fair Value Measurements	Available-for-sale The fair value of cash, cash equivalents and available-for-sale in thousands As of December 31, 2016 As of December 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 24,340 $ — $ — $ 24,340 $ 46,383 $ — $ — $ 46,383 Investment securities: Commercial paper — 8,996 — 8,996 — 7,992 — 7,992 Corporate debt securities — 49,125 — 49,125 — 94,782 — 94,782 U.S. government and government agency obligations 50,499 — — 50,499 22,992 — — 22,992 Total investment securities 50,499 58,121 — 108,620 22,992 102,774 — 125,766 Total assets measured at fair value $ 74,839 $ 58,121 $ — $ 132,960 $ 69,375 $ 102,774 $ — $ 172,149 The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, 2, or 3 for the years ended December 31, 2016 and 2015.

Investment Securities (Tables)

Investment Securities (Tables)	12 Months Ended
	Dec. 31, 2016
Investments Schedule [Abstract]
Summary of Available for Sale Investments Held by the Company	Following is a summary of the available-for-sale in thousands As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Available-for-sale Commercial paper $ 8,996 $ — $ — $ 8,996 Corporate debt securities 49,179 1 (55 ) 49,125 U.S. government and agency obligations 50,568 1 (70 ) 50,499 Total $ 108,743 $ 2 $ (125 ) $ 108,620 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Available-for-sale Commercial paper $ 7,992 $ — $ — $ 7,992 Corporate debt securities 94,959 3 (180 ) 94,782 U.S. government and agency obligations 23,064 — (72 ) 22,992 Total $ 126,015 $ 3 $ (252 ) $ 125,766

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Cash, Cash Equivalents and Available-for-Sale Investment Securities	The fair value of cash, cash equivalents and available-for-sale in thousands As of December 31, 2016 As of December 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 24,340 $ — $ — $ 24,340 $ 46,383 $ — $ — $ 46,383 Investment securities: Commercial paper — 8,996 — 8,996 — 7,992 — 7,992 Corporate debt securities — 49,125 — 49,125 — 94,782 — 94,782 U.S. government and government agency obligations 50,499 — — 50,499 22,992 — — 22,992 Total investment securities 50,499 58,121 — 108,620 22,992 102,774 — 125,766 Total assets measured at fair value $ 74,839 $ 58,121 $ — $ 132,960 $ 69,375 $ 102,774 $ — $ 172,149

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following ( in thousands December 31, 2016 December 31, 2015 Lab and manufacturing equipment $ 7,656 $ 6,941 Computer and office equipment 1,762 1,145 Leasehold improvements 374 2,349 Property and equipment at cost 9,792 10,435 Less accumulated depreciation and amortization (3,522 ) (2,671 ) Subtotal 6,270 7,764 Construction in process (see below) — 11,000 Property and equipment, net $ 6,270 $ 18,764
Schedule of Other Long-term Liabilities	Other long-term liabilities consisted of the following ( in thousands December 31, 2016 December 31, 2015 Leased facility financing obligation (see below) $ — $ 11,000 Final loan fee obligation to lender (see note 6) 1,600 930 Other long-term liabilities 1,510 234 Total $ 3,110 $ 12,164

Note Payable (Tables)

Note Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Future Minimum Principal Payments on Notes Payable	Future minimum principal payments under the Company’s note payable are as follows ( in thousands Year ending December 31, Minimum Payments 2017 $ — 2018 5,333 2019 10,667 2020 10,667 2021 5,333 Total $ 32,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Non-cancellable Future Minimum Annual Lease Payments Under Operating Leases	The Company’s non-cancellable (in thousands): Minimum 2017 $ 2,552 2018 4,572 2019 4,593 2020 4,731 2021 4,873 Thereafter 4,162 Total minimum lease payments $ 25,483

Equity Awards (Tables)

Equity Awards (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity and Other Related Information	A summary of stock option activity during the year ended December 31, 2016, and other related information, is as follows: Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Term Aggregate Intrinsic Value Balance at December 31, 2015 5,250,941 $ 9.16 Granted 1,276,641 $ 8.17 Exercised (126,698 ) $ 3.24 Forfeited (1,291,599 ) $ 9.92 Balance at December 31, 2016 5,109,285 $ 8.86 7.85 $ 834,601 Exercisable at December 31, 2016 2,284,866 $ 8.00 6.91 $ 760,794
Assumptions Used to Estimate Fair Value of Stock Option Grants	The weighted-average assumptions used to estimate the fair value of stock option grants were as follows: Year ended December 31, 2016 2015 2014 Volatility 77 % 69 % 65 % Expected life of option 6.4 years 6.2 years 6.0 years Risk free interest rate 1.5 % 1.7 % 1.8 % Dividend yield — % — % — %
Summary of Stock-Based Compensation Expense for Equity Awards Including RSUs to Employees and Non-Employees	The following table summarizes stock-based compensation expense for all equity awards, including RSUs, issued to employees and non-employees in thousands Year ended December 31, 2016 2015 2014 Included in research and development $ 3,464 $ 2,576 $ 896 Included in general and administrative 4,257 2,769 1,387 Total $ 7,721 $ 5,345 $ 2,283

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Statutory Federal Income Tax Provision to Actual Income Tax Provision	A reconciliation of the statutory federal income tax provision to the actual income tax provision is as follows ( in thousands Year ended December 31, 2016 2015 2014 Expected income tax benefit at federal statutory rate $ (35,237 ) $ (31,436 ) $ (13,597 ) State income tax benefit, net of federal benefit (2,837 ) (5,438 ) (2,245 ) Research credits (3,480 ) (1,854 ) (1,118 ) Intangible related to asset acquisition — (1,247 ) — Uncertain tax positions 3,476 1,386 — Other 812 13 162 Change in valuation allowance 37,266 38,576 16,798 Income tax expense (benefit) $ — $ — $ —
Summary of Unrecognized Tax Benefits	The following table summarizes the changes in the amount of the Company’s unrecognized tax benefits ( in thousands Year ended December 31, 2016 2015 2014 Beginning balance $ 2,100 $ — $ — Increase (decrease) for prior year tax positions 5,267 2,100 — Increase (decrease) for current year tax positions — — — Income tax expense (benefit) $ 7,367 $ 2,100 $ —
Summary of Significant Components of Company's Deferred Tax Assets	The significant components of the Company’s deferred tax assets are comprised of the following ( in thousands December 31, 2016 2015 Net operating loss carryforwards $ 68,427 $ 35,131 Tax credit carryforwards 6,571 3,224 Stock-based compensation 5,104 2,848 Accrued compensation 1,295 1,485 Intangible assets recognized for tax purposes 11,856 13,143 In process research and development charge 5,376 5,865 Other, net 680 846 Total deferred tax assets 99,309 62,542 Deferred tax liabilities (depreciation) (610 ) (1,060 ) Valuation allowance (98,699 ) (61,482 ) Net deferred tax assets $ — $ —

Quarterly Data (unaudited) (Tab

Quarterly Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Data	The following quarterly financial data, in the opinion of management, reflects all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of results for the periods presented (in thousands, except per share amounts): Year Ended December 31, 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Research and development expenses $ 19,781 $ 20,019 $ 16,626 $ 20,500 Total operating expenses $ 25,008 $ 25,518 $ 22,771 $ 27,387 Net loss $ (25,492 ) $ (26,651 ) $ (23,289 ) $ (28,208 ) Net loss per share – basic and diluted $ (0.79 ) $ (0.70 ) $ (0.56 ) $ (0.68 ) Year Ended December 31, 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Research and development expenses (1)(2) $ 20,215 $ 8,796 $ 10,432 $ 34,068 Total operating expenses $ 22,982 $ 12,651 $ 14,289 $ 40,658 Net loss $ (23,507 ) $ (13,120 ) $ (14,621 ) $ (41,210 ) Net loss per share – basic and diluted $ (1.15 ) $ (0.51 ) $ (0.49 ) $ (1.32 ) (1) First quarter 2015 results include an up-front non-cash (2) Fourth quarter 2015 results include an up-front non-cash

Organization - Additional Infor

Organization - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segment | Segment	1
Net cash used in operating activities	$ (90,110)	$ (50,800)	$ (32,488)
Accumulated deficit	(251,660)	$ (148,021)
Cash, cash equivalents and investment securities	$ 133,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Line Items]
Other-than-temporary impairment charges	$ 0
Antidilutive securities excluded from computation of earnings per share	5.5	5.4
Minimum [Member]
Accounting Policies [Line Items]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Accounting Policies [Line Items]
Estimated useful lives of property and equipment	7 years

Investment Securities - Summary

Investment Securities - Summary of Available for Sale Investments Held by the Company (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	$ 108,743	$ 126,015
Available-for-sale investment securities, Gross Unrealized Gains	2	3
Available-for-sale investment securities, Gross Unrealized Losses	(125)	(252)
Available-for-sale investment securities, Fair Market Value	108,620	125,766
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	8,996	7,992
Available-for-sale investment securities, Fair Market Value	8,996	7,992
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	49,179	94,959
Available-for-sale investment securities, Gross Unrealized Gains	1	3
Available-for-sale investment securities, Gross Unrealized Losses	(55)	(180)
Available-for-sale investment securities, Fair Market Value	49,125	94,782
U.S. Government and Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	50,568	23,064
Available-for-sale investment securities, Gross Unrealized Gains	1
Available-for-sale investment securities, Gross Unrealized Losses	(70)	(72)
Available-for-sale investment securities, Fair Market Value	$ 50,499	$ 22,992

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Available-for-Sale Investment Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 24,340	$ 46,383
Total investment securities	108,620	125,766
Total assets measured at fair value	132,960	172,149
Investment Securities [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	8,996	7,992
Investment Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	49,125	94,782
Investment Securities [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	50,499	22,992
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	24,340	46,383
Total investment securities	50,499	22,992
Total assets measured at fair value	74,839	69,375
Level 1 [Member] | Investment Securities [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	50,499	22,992
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	58,121	102,774
Total assets measured at fair value	58,121	102,774
Level 2 [Member] | Investment Securities [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	8,996	7,992
Level 2 [Member] | Investment Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investment securities	$ 49,125	$ 94,782

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Transfers of assets into level 3	0	0
Transfers of assets out of level 3	$ 0	$ 0

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Lab and manufacturing equipment	$ 7,656	$ 6,941
Computer and office equipment	1,762	1,145
Leasehold improvements	374	2,349
Property and equipment at cost	9,792	10,435
Less accumulated depreciation and amortization	(3,522)	(2,671)
Subtotal	6,270	7,764
Property and equipment, net	$ 6,270	18,764
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Construction in process		$ 11,000

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Leased facility financing obligation to replace cost of buildings		$ 11,000,000
Lab and Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Capital leased assets gross	$ 600,000
Capital leased assets net	400,000	500,000
Depreciation	$ 100,000	100,000	$ 17,000
Level 3 [Member]
Property, Plant and Equipment [Line Items]
Leased facility financing obligation to replace cost of buildings		$ 11,000,000

Balance Sheet Details - Sched36

Balance Sheet Details - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities [Abstract]
Leased facility financing obligation		$ 11,000
Final loan fee obligation to lender	$ 1,600	930
Other long-term liabilities	1,510	234
Total	$ 3,110	$ 12,164

Note Payable - Additional Infor

Note Payable - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Total debt			$ 32,000,000
Loss on debt extinguishment			$ 696,000
Common Stock Warrant [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock			153,472
Exercise price of common stock			$ 5.75
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Total debt	$ 32,000,000	$ 32,000,000
Loss on debt extinguishment		700,000
Term loan facility, interest rate			8.10%
Term loan facility, payment terms			Borrowings under the new facility will bear interest at a rate equal to the Prime Rate plus 4.35% (8.10% at December 31, 2016) and have interest only payments for twenty-four months, followed by a principal amortization period of thirty-six months.
Final lump-sum payment at maturity as a percentage of principal amount	5.00%
Lump sum payment to be paid	$ 1,600,000	1,600,000
Warrant term	7 years
Debt Instrument, covenant description			The Company must also maintain the majority of its cash in accounts at SVB. Upon the occurrence of an event of default, subject to cure periods for certain events of default, all amounts owed by the Company thereunder shall begin to bear interest at a rate that is 3% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lenders.
Silicon Valley Bank [Member] | Second Tranche [Member]
Debt Instrument [Line Items]
Term loan facility amount	$ 10,000,000	10,000,000
Warrant term	7 years
Warrants exercisable, aggregate shares	$ 150,000	$ 150,000
Warrants issuable as percentage of funded amount	1.50%	1.50%
Number of days considered to arrive at exercise price to issue warrants	10 days
Silicon Valley Bank [Member] | First Twelve Months [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid	2.00%
Silicon Valley Bank [Member] | Thereafter [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid	1.00%
Silicon Valley Bank [Member] | Common Stock Warrant [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	94,116	94,116
Exercise price of common stock	$ 5.10	$ 5.10
Silicon Valley Bank [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Term loan facility, variable interest rate			4.35%

Note Payable - Future Minimum P

Note Payable - Future Minimum Principal Payments on Notes Payable (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Debt Disclosure [Abstract]
2,017	$ 0
2,018	5,333
2,019	10,667
2,020	10,667
2,021	5,333
Total	$ 32,000

Asset Acquisition - Additional

Asset Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Dec. 31, 2015
Noncash or Part Noncash Acquisitions [Line Items]
In-process research and development charge associated with asset acquisition		$ 11,880	$ 11,880
Cephalon Inc [Member] | Drug Development Supplies [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Payments to acquire drug development supplies		$ 900
Unregistered Common Stock [Member] | Cephalon Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Stock issued for purchase of asset	1,500,000	1,500,000

License Agreements - Additional

License Agreements - Additional Information (Detail) - USD ($) $ in Millions	Nov. 06, 2015	Nov. 06, 2013	Nov. 30, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License agreement term						5 years
RXDX-105 and RXDX-106 [Member] | Daiichi Sankyo [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License agreement termination notice period						90 days
RXDX-108 [Member] | Daiichi Sankyo [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License expiration term						10 years
License Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments	$ 38
Annual license payments	2	$ 7		$ 10	$ 2	$ 17
Issuance of common stock			1,500,000
Change in value of share issued	$ 13.4				$ 13.4
Net proceeds from issuance of shares			$ 30
License Agreements [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments		$ 105
Royalties percentage		15.00%
License Agreements [Member] | Maximum [Member] | RXDX-105 [Member] | Daiichi Sankyo [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments						44.5
License Agreements [Member] | Maximum [Member] | RXDX-106 [Member] | Daiichi Sankyo [Member] | Upon Achievement of Development Regulatory and Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments						47.5
License Agreements [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties percentage		10.00%
License Agreements [Member] | Private Investment in Public Equity ( the "PIPE" Financing") [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock	1,213,000
Net proceeds from issuance of shares						$ 30

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Operating lease lease expiration period	10 years
Operating leases, description		The lease also contains a one-time provision to terminate the lease for all or a portion of the facilities, effective as of the end of the 72nd month after the lease commencement date, subject to the payment of a termination fee defined in the lease agreement.
Operating leases, rent expense		$ 1.5	$ 0.6	$ 0.5
Operating leases, expiration dates		Operating leases that expire through 2018.
Rent commenced date		2016-10
Free rent period		10 years
Clinical expenses incurred to date		$ 30.6
California [Member]
Loss Contingencies [Line Items]
Operating leases, ground rental expense		0.5
Lab Equipment [Member]
Loss Contingencies [Line Items]
Future minimum capital lease payments		0.2
Research and Development Arrangement [Member]
Loss Contingencies [Line Items]
Clinical expenses total contracted cost		$ 79

Commitments and Contingencies42

Commitments and Contingencies - Schedule of Non-cancellable Future Minimum Annual Lease Payments Under Operating Leases (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Leases [Abstract]
2,017	$ 2,552
2,018	4,572
2,019	4,593
2,020	4,731
2,021	4,873
Thereafter	4,162
Total minimum lease payments	$ 25,483

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended						12 Months Ended
	May 31, 2016	Dec. 31, 2015	Nov. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized		150,000,000					150,000,000	150,000,000
Preferred stock, shares authorized		10,000,000					10,000,000	10,000,000
Common Stock, voting right description							Common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
Common Stock [Member]
Class of Stock [Line Items]
Stock issued and sold	9,200,000			4,285,714		6,031,750	9,200,000	9,944,464	6,031,750
Net proceeds from issuance of shares	$ 53,900,000			$ 70,100,000		$ 51,600,000
Transaction costs	$ 3,600,000			$ 4,900,000		$ 3,600,000
Common Stock Warrant [Member]
Class of Stock [Line Items]
Warrant to purchase stock, shares							153,472
Warrant to purchase stock, weighted average exercise price per share							$ 5.75
Common Stock Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrants expiration date							2023-06
License Agreements [Member]
Class of Stock [Line Items]
Stock issued and sold			1,500,000
Net proceeds from issuance of shares			$ 30,000,000
License Agreements [Member] | Shelf Registration Statement [Member]
Class of Stock [Line Items]
Percentage of commission paid on gross proceeds of sales		3.00%
Common stock value		$ 33,000,000						$ 33,000,000
Cephalon Inc [Member]
Class of Stock [Line Items]
Stock issued and sold					4,158,750
Net proceeds from issuance of shares					$ 41,400,000
Transaction costs					$ 149,000

Equity Awards - Additional Info

Equity Awards - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 11, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated weighted-average fair value of stock options granted	$ 5.25	$ 7.25	$ 4.72
Unrecognized stock-based compensation expense related to unvested stock-based awards	$ 15.5
Employee and Non-employee Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of equity awards				6,000,000
Employee and Non-employee Stock Options [Member] | 2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Employee and Non-employee Stock Options [Member] | 2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued for each share subject to a stock option granted	100.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested stock-based awards, weighted average period of recognition	2 years 7 months 6 days
Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares that remained available for grant	3,525,680
Stock Options [Member] | 2014 Inducement Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional equity grants	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional equity grants	206,880	90,000
Shares subject to future vesting	238,480

Equity Awards - Summary of Stoc

Equity Awards - Summary of Stock Option Activity and Other Related Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Options Outstanding
Balance at beginning of period | shares	5,250,941
Granted | shares	1,276,641
Exercised | shares	(126,698)
Forfeited and expired | shares	(1,291,599)
Balance at end of period | shares	5,109,285
Exercisable at end of period | shares	2,284,866
Weighted-Average Exercise Price
Balance at beginning of period | $ / shares	$ 9.16
Granted | $ / shares	8.17
Exercised | $ / shares	3.24
Forfeited and expired | $ / shares	9.92
Balance at end of period | $ / shares	8.86
Exercisable at end of period | $ / shares	$ 8
Weighted- Average Remaining Contractual Term
Balance at end of period	7 years 10 months 6 days
Exercisable at end of period	6 years 10 months 28 days
Aggregate Intrinsic Value
Balance at end of period | $	$ 834,601
Exercisable at end of period | $	$ 760,794

Equity Awards - Assumptions Use

Equity Awards - Assumptions Used to Estimate Fair Value of Stock Option Grants (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Volatility	77.00%	69.00%	65.00%
Expected life of option	6 years 4 months 24 days	6 years 2 months 12 days	6 years
Risk free interest rate	1.50%	1.70%	1.80%
Dividend yield	0.00%	0.00%	0.00%

Equity Awards - Summary of St47

Equity Awards - Summary of Stock-Based Compensation Expense for Equity Awards Including RSUs to Employees and Non-Employees (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	$ 7,721	$ 5,345	$ 2,283
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	3,464	2,576	896
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	$ 4,257	$ 2,769	$ 1,387

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Expected income tax benefit at federal statutory rate	$ (35,237)	$ (31,436)	$ (13,597)
State income tax benefit, net of federal benefit	(2,837)	(5,438)	(2,245)
Research credits	(3,480)	(1,854)	(1,118)
Intangible related to asset acquisition		(1,247)
Uncertain tax positions	3,476	1,386
Other	812	13	162
Change in valuation allowance	37,266	38,576	16,798
Income tax expense (benefit)	$ 0	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Income Tax [Line Items]
Unrecognized tax benefits that would not impact income tax	$ 4.8
Operating loss carryforward related to tax deductions	$ 1
Federal and state tax net operating loss carryforwards, beginning period of expiration	2,031
Operating loss and credit carryforwards limitation	An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period.
State and Local [Member]
Income Tax [Line Items]
Net operating losses	$ 138.8
Tax credit carry forwards	$ 3.3
Federal [Member]
Income Tax [Line Items]
Net credit carryforwards, beginning period of expiration	2,031
Net operating losses	$ 192.3
Tax credit carry forwards	$ 4.4

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 2,100
Increase (decrease) for prior year tax positions	5,267	$ 2,100
Increase (decrease) for current year tax positions	0	0	$ 0
Income tax expense (benefit)	$ 7,367	$ 2,100

Income Taxes - Summary of Signi

Income Taxes - Summary of Significant Components of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Components of Deferred Tax Assets [Abstract]
Net operating loss carryforwards	$ 68,427	$ 35,131
Tax credit carryforwards	6,571	3,224
Stock-based compensation	5,104	2,848
Accrued compensation	1,295	1,485
Intangible assets recognized for tax purposes	11,856	13,143
In process research and development charge	5,376	5,865
Other, net	680	846
Total deferred tax assets	99,309	62,542
Deferred tax liabilities (depreciation)	(610)	(1,060)
Valuation allowance	(98,699)	(61,482)
Net deferred tax assets	$ 0	$ 0

Quarterly Data - Schedule of Qu

Quarterly Data - Schedule of Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Research and development expenses	$ 20,500	$ 16,626	$ 20,019	$ 19,781	$ 34,068	$ 10,432	$ 8,796	$ 20,215	$ 76,926	$ 73,511	$ 30,505
Total operating expenses	27,387	22,771	25,518	25,008	40,658	14,289	12,651	22,982	100,684	90,580	40,011
Net loss	$ (28,208)	$ (23,289)	$ (26,651)	$ (25,492)	$ (41,210)	$ (14,621)	$ (13,120)	$ (23,507)	$ (103,639)	$ (92,458)	$ (39,990)
Net loss per share - basic and diluted	$ (0.68)	$ (0.56)	$ (0.70)	$ (0.79)	$ (1.32)	$ (0.49)	$ (0.51)	$ (1.15)	$ (2.69)	$ (3.44)	$ (2.18)

Quarterly Data - Schedule of 53

Quarterly Data - Schedule of Quarterly Financial Data (Parenthetical) (Detail) - USD ($) $ in Thousands	Nov. 06, 2015	Nov. 06, 2013	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Interim Reporting [Line Items]
In-process research and development charge associated with asset acquisition						$ 11,880		$ 11,880
License Agreements [Member]
Interim Reporting [Line Items]
Annual license payments	$ 2,000	$ 7,000		$ 10,000	$ 2,000		$ 17,000
Change in value of share issued	$ 13,400				$ 13,400
License Agreements [Member] | Private Investment in Public Equity ( the "PIPE" Financing") [Member]
Interim Reporting [Line Items]
Issuance of common stock					1,213,000
Cephalon Inc [Member] | Unregistered Common Stock [Member]
Interim Reporting [Line Items]
Stock issued for purchase of asset			1,500,000			1,500,000
Cephalon Inc [Member] | Drug Development Supplies [Member]
Interim Reporting [Line Items]
Payments to acquire drug development supplies						$ 900